Lifetime cancer risks for individuals with a BAP1 GPV (henceforth referred to as BAP1 carriers) are reported to be 20–25% for mesothelioma, uveal and cutaneous melanoma, with lower lifetime risks reported for renal cell carcinoma and other associated cancers. This evidence concerns the gene BAP1 and hereditary clear cell renal cell carcinoma.